Last reviewed · How we verify

Sedation Propofol

RenJi Hospital · FDA-approved active Small molecule

Propofol is a rapid-acting intravenous sedative-hypnotic that enhances inhibitory GABA neurotransmission in the central nervous system.

Propofol is a rapid-acting intravenous sedative-hypnotic that enhances inhibitory GABA neurotransmission in the central nervous system. Used for Induction and maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care units.

At a glance

Generic nameSedation Propofol
Also known asEP
SponsorRenJi Hospital
Drug classIntravenous sedative-hypnotic
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia/Sedation
PhaseFDA-approved

Mechanism of action

Propofol acts as a positive allosteric modulator of GABA-A receptors, increasing chloride ion influx and neuronal hyperpolarization, which results in sedation and unconsciousness. It has a rapid onset (within seconds) and short duration of action due to rapid redistribution from the central nervous system to peripheral tissues and subsequent hepatic metabolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: